Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Tamsulosin · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Comparator | ACTIVE_COMPARATOR | Tamsulosin 0.4 mg prolonged release |
| Treatment Arm | EXPERIMENTAL | There are 5 possible UK-369,003 arms as follows: UK-369,003 MR (10mg, 25mg, 50mg \& 100mg), UK-369,003 IR (40mg), |
| Name | Type | Description |
|---|---|---|
| Tamsulosin | DRUG | Tamsulosin hydrochloride capsules, 0.4 mg. Tamsulosin hydrochloride is an antagonist of alpha1A adrenoceptors in the prostate |
| UK-369,003 | DRUG | UK 369,003 is a highly selective and potent inhibitor of PDE5. It has increased selectivity for PDE5 over PDE6 (\>80 fold) compared to sildenafil (\~10 fold). Two recently completed trials have shown efficacy for UK-369,003 in treating subjects with ED |
Inclusion Criteria: 1. Male subjects aged 40 years and above, with documented LUTS with an International Prostate Symptom Score (IPSS) ≥13 2. Clinical diagnosis of BPH. 3. Qmax 5 to 15ml/sec with a voided volume of ≥150ml at visit 1 (screening). Exclusion Criteria: 1. Urinary tract infection 2. P...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Boston Scientific Corporation | BSX | 2 | - | Undisclosed |
| PROCEPT BioRobotics Corp. | PRCT | 2 | N/A | Undisclosed |
| EDAP TMS SA Sponsored ADR | EDAP | 1 | N/A | Undisclosed |
| Profound Medical Corp | PROF | 1 | - | Undisclosed |
Tamsulosin is an investigational small molecule being studied for the treatment of Prostatic Hyperplasia, a condition also known as benign prostatic hyperplasia. It is being developed by Pfizer, Inc. and is currently in Phase 2 clinical development for this indication.
Tamsulosin is being developed by Pfizer, Inc., a biopharmaceutical company listed on the New York Stock Exchange under the ticker symbol PFE. The company is conducting clinical research to evaluate the drug's effects in patients with Prostatic Hyperplasia.
Tamsulosin is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The drug is being studied for its potential use in treating Prostatic Hyperplasia, and its safety and efficacy are still being evaluated in clinical trials.
Tamsulosin has been studied in one completed Phase 2 clinical trial, identified as NCT00457457. This trial, titled "Study the Effects of Different Doses of UK-369,003 in Men With Lower Urinary Tract Symptoms," enrolled 609 male participants aged 40 years and older with Prostatic Hyperplasia.
Yes, Tamsulosin is also known as UK-369,003. The Phase 2 clinical trial NCT00457457 used the name UK-369,003 in its title, confirming that both names refer to the same investigational drug being developed by Pfizer, Inc. for Prostatic Hyperplasia.
Tamsulosin is a small molecule being studied for Prostatic Hyperplasia. The specific molecular target of the drug has not been disclosed in available clinical trial information, so its mechanism of action is not detailed here. The drug is being evaluated for its effects on lower urinary tract symptoms in men.